What is DermaSensor?
DermaSensor operates at the forefront of medical innovation, specializing in AI-driven precision tools designed for the non-invasive assessment of skin lesions. By providing healthcare providers with an FDA-cleared device, the company effectively bridges the gap between primary care screenings and specialized dermatological referrals. Its technology is engineered to enhance clinical confidence, allowing practitioners in internal medicine, family medicine, and medical aesthetics to perform rapid, accurate evaluations at the point of care. This strategic positioning not only streamlines the diagnostic workflow but also addresses critical inefficiencies in early-stage skin cancer detection, ultimately improving patient prognosis through timely intervention.
How much funding has DermaSensor raised?
DermaSensor has raised a total of $16M across 1 funding round:
Series B
$16M
Series B (2025): $16M with participation from GenHenn Capital, Kern Venture Group, and Pier 70 Ventures
Key Investors in DermaSensor
GenHenn Capital
GenHenn Capital is a venture capital firm focused on investing in early-stage life sciences, healthcare, and biotech companies that are developing high-impact solutions.
Kern Venture Group
Kern Venture Group is a venture capital firm based in the Central Valley of California that focuses on bridging gaps and fostering innovation in early-stage to Series B investments.
Pier 70 Ventures
Pier 70 Ventures invests in impact-driven technologies, particularly in healthcare, providing capital and mentorship to accelerate high-growth sustainable companies.
What's next for DermaSensor?
Looking ahead, the recent capital influx will likely be deployed to accelerate the commercial rollout of DermaSensor's diagnostic suite and deepen its integration within existing healthcare ecosystems. As the company transitions from its current development phase into a broader market-scaling strategy, the focus will shift toward expanding its footprint in clinical settings and refining its AI algorithms through increased data acquisition. The support from its current investor base provides not only the necessary financial runway but also the strategic guidance required to navigate regulatory landscapes and foster long-term adoption among healthcare professionals. Future growth will be defined by the company's ability to maintain its technological edge while scaling its operational infrastructure to meet the rising demand for point-of-care diagnostic solutions.
See full DermaSensor company page
